Project Grant R01NS131658
- Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded Cleveland Clinic Lerner College of Medicine of Case Western Reserve University a $877,250 Project Grant on May 6, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). This exploratory research initiative, with a completion date of April 30, 2028, investigates aberrant N6-methyladenosine (M6A) methylation patterns in hippocampal neurons...
- This Project Grant award of $414,191 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) will fund research by Drexel University investigating the relationship between structural variations in alpha-synuclein (α-syn) protein fibrils and the development of distinct neurodegenerative synucleinopathies such as Lewy body dementia, Parkinson's disease, and multiple system atrophy....
- This Project Grant award from the National Institutes of Health's Aging Research program (CFDA 93.866) will support research to identify early transcriptional and pathological changes in brain regions vulnerable to Alzheimer's disease (AD). The $459,076 award, granted to Trustees of Boston University, will use single-nucleus RNA sequencing and targeted mass spectrometry to profile cell type-specific gene expression and tau/amyloid beta proteoforms in the transentorhinal cortex, entorhinal...
- Federal Project Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $669,891 Project Grant to the Icahn School of Medicine at Mount Sinai on February 3, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The award funds a comprehensive five-year research initiative (through January 30, 2031) investigating the genetic, transcriptomic, and immunohistochemical basis of Progressive...
- Federal Project Grant Summary Award Details: Mayo Clinic Jacksonville received a $622,792 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), awarded May 20, 2026, with completion targeted for April 30, 2031. Research Products and Services: The grant funds a multi-omic research initiative to identify transcriptomic and genomic signatures that...
- The University of Massachusetts Medical School (UMass Medical) was awarded a $1,507,500 Project Grant from the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866) to conduct a study on spatial single-cell analysis of somatic mutations in the human brain during aging and neurodegeneration. The goal is to develop and apply new single-cell whole-genome sequencing methods to study somatic mutations in neurons from late-stage Alzheimer's disease and...
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded Cleveland Clinic Lerner College of Medicine of Case Western Reserve University $544,568 on February 11, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). This Project Grant supports basic research investigating the pathogenesis of permanent neurological disability in multiple sclerosis (MS), with performance through December 31,...
- Federal Project Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded $137,828 to the University of Massachusetts Medical School (UMMS) on November 1, 2025, under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The three-year project, concluding October 31, 2028, will conduct single-cell analysis to characterize how loss-of-function mutations in the ATM (A-T Mutated) gene impact somatic mutation...
- This Project Grant award of $423,994 from the National Institute on Aging (CFDA 93.866 - Aging Research) to Duke University aims to characterize spatial variations in RNA isoform expression in relation to Alzheimer's disease (AD) pathology. The research will leverage single-nucleus cDNA, long-read RNA sequencing, and in situ sequencing to profile isoform expression at single-cell resolution in the inferior frontal gyrus, a brain region pertinent to AD. The study will identify cell-type...
- Summary The Jackson Laboratory received a $486,750 Project Grant from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), awarded June 15, 2026, with completion scheduled for May 31, 2028. The award funds the development and validation of a human tri-culture microphysiological system designed to study myelination and axonal-synaptic pathology in Alzheimer's disease (AD). The primary deliverable is an integrated microfluidic platform that co-cultures neurons,...
SINGLE CELL TRANSCRIPTOMIC PROFILING OF MULTIPLE SYSTEM ATROPHY BRAIN - PROJECT SUMMARY/ABSTRACT MULTIPLE SYSTEM ATROPHY (MSA) IS A RARE PROGRESSIVE NEURODEGENERATIVE DISEASE CHARACTERIZED BY SELECTIVE ACCUMULATION OF A-SYNUCLEIN IN GLIAL CYTOPLASMIC INCLUSIONS (GCIS) WITHIN OLIGODENDROCYTES. CLINICALLY, MSA PATIENTS PRESENT WITH VARIOUS COMBINATIONS OF PARKINSONISM, CEREBELLAR DYSFUNCTION, AND DYSAUTONOMIA. MSA IS SUBCLASSIFIED BASED ON PREDOMINANCE OF SYMPTOMOLOGY, WHICH IS ASSOCIATED WITH THE PRIMARY SITE OF NEURODEGENERATION: MSA-P FOR PARKINSONISM AND STRIATONIGRAL DEGENERATION OR MSA-C FOR CEREBELLAR FEATURES AND OLIVOPONTOCEREBELLAR ATROPHY, THOUGH MOST CASES INVOLVE BOTH SYSTEMS. THE CAUSES OF A-SYNUCLEIN ACCUMULATION WITHIN OLIGODENDROCYTES AND ITS CONSEQUENCES TO OLIGODENDROCYTE PHYSIOLOGY IN MSA ARE LARGELY UNKNOWN. LIKEWISE, HOW OLIGODENDROCYTE DYSFUNCTION CAUSES NEURONAL DEATH REMAINS OBSCURE. IN THIS PROPOSAL, WE WILL USE SINGLE NUCLEUS RNA SEQUENCING (SNRNA-SEQ) TO GENERATE TRANSCRIPTOMES OF SINGLE CELLS FROM POSTMORTEM BRAIN TISSUE FROM MSA PATIENTS TO DELINEATE THE CELL TYPE SPECIFIC TRANSCRIPTIONAL CHANGES ASSOCIATED WITH MSA. WE WILL PROBE STRIATAL, CEREBELLAR, AND CORTICAL TISSUE SETS FROM THE SAME MSA-P OR MSA- C PATIENTS. THIS ALLOWS US TO CAPTURE THE CHANGES THAT OCCUR IN THE PRIMARY SITE OF PATHOLOGY FOR EACH MSA SUBTYPE, STRIATUM FOR MSA-P AND CEREBELLUM FOR MSA-C, ALONG WITH THE SECONDARY SITES, AND A MINIMALLY AFFECTED BRAIN REGION (CORTEX). IN AIM 1, WE WILL COLLECT ADDITIONAL MSA CASES AND GENERATE SNRNA-SEQ PROFILES FROM ALL TISSUE SETS. THESE DATA WILL BE INTEGRATED AND CLUSTERED TO IDENTIFY MAJOR CELL TYPES AND SUBTYPES FROM WHICH INFORMATIC ANALYSIS OF DIFFERENTIALLY-EXPRESSED GENES WILL BE USED TO IDENTIFY REGULATORY NETWORKS AND INFER CHANGE IN FUNCTION. IN AIM 2, WE WILL TEST WHETHER CELLS WITH ALTERED TRANSCRIPTIONAL PROFILES IDENTIFIED BY SNRNA- SEQ CORRESPOND TO THE CELLS WITH PATHOLOGICAL FEATURES OF MSA OR TO CELLS EXHIBITING DYSFUNCTION USING IMMUNOHISTOCHEMISTRY AND MULTIPLEXED FLUORESCENCE IN SITU HYBRIDIZATION WITH RNASCOPE. INITIALLY FOCUSING ON OLIGODENDROCYTES, WE WILL DETERMINE WHETHER CELLS BEARING GCI EXHIBIT DYSREGULATED TRANSCRIPTOMES, WHETHER A- SYNUCLEIN MRNA IS OVEREXPRESSED IN THESE CELLS, AND WHETHER THIS AFFECTS MYELIN INTEGRITY. IN AIM 3, WE WILL TEST WHETHER FORCED OVEREXPRESSION OF A-SYNUCLEIN IN OLIGODENDROCYTES IS SUFFICIENT TO RECAPITULATE THE SNRNA-SEQ PROFILES OBTAINED FROM MSA TISSUES USING A NONHUMAN PRIMATE MSA MODEL. UPON COMPLETION, THIS PROPOSAL WILL GENERATE AN ATLAS OF THE MSA-DEPENDENT TRANSCRIPTIONAL CHANGES OF NEARLY ALL CELL TYPES IN THE STRIATUM, CEREBELLUM, AND CORTEX, IDENTIFY KEY ALTERATIONS IN GENE EXPRESSION AND THE PATHWAYS AFFECTED, DETERMINE WHETHER A-SYNUCLEIN EXPRESSION IS INCREASED IN CELLS WITH GCI, AND WHETHER DE NOVO EXPRESSION OF A-SYNUCLEIN MRNA FULLY RECAPITULATES THE CELL STATES ASSOCIATED WITH MSA.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $650.6k | 7/28/25 | ||
| Not listed | $143.5k | 9/11/24 | ||
| Not listed | $666.1k | 7/22/24 | ||
| Not listed | $666.1k | 7/22/24 |
GrantNumber | Description | Subgrantee | Prime Award | Dollars Obligated | Updated At |
|---|---|---|---|---|---|
SUB00007942S | Arizona State University | Project Grant R01NS131658 | $81.2k | 12/5/25 |